louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04429178: Portal Vein Pulsatility Flow in Pregnancy
Official title: Portal Vein Pulsatility Flow in Pregnancy - a Pilot Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pregnancy
Keywords: portal vein pulsatility
physiologic volume overload
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2020-06-12
Enrollment: 80
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Pregnant women attending either the anaesthetic preassessment clinic or the obstetric ultrasound clinic at University Hospital Basel.

Non-pregnant healthy females fulfilling the inclusion criteria will be recruited by published advertisement at the University Hospital Basel.

Brief summary: This study is to investigate if portal vein pulsatility fraction can be measured in pregnancy and if it increases during the course of pregnancy as would be expected by the physiologic increase in blood volume that happens during pregnancy. Portal vein pulsatility fraction is measured in non-pregnant controls and in women in the 1st, 2nd and 3rd trimester of pregnancy.


Eligibility criteria: Inclusion Criteria:

* Ability to give informed consent
* American Society of Anesthesiologists (ASA) Class I and II
* Singleton pregnancy during 1st, 2nd or 3rd trimester or healthy non-pregnant females of childbearing age as controls

Exclusion Criteria:

* Inability to give informed consent
* Multiple gestation
* Significant co-morbidities (e.g. cardiac abnormalities, cardiac dysfunction, arrhythmias, severe asthma, renal insufficiency)
* High risk pregnancies (e.g. pre-eclampsia, gestational hypertension, HELLP, gestational diabetes)
* Body-Mass-Index (BMI) \< 18kg/m2 or \>40kg/m2

Primary outcomes:
measure: Portal vein pulsatility fraction (percent)
timeFrame: single time-point at baseline
Secondary outcomes:
measure: Inferior vena cava diameter (mm)
timeFrame: single time-point at baseline
measure: Inferior vena cava collapsibility index (percent)
timeFrame: single time-point at baseline
measure: Hepatic venous flow (cm/sec)
timeFrame: single time-point at baseline
measure: Right atrial and ventricular dimensions (cm)
timeFrame: single time-point at baseline
measure: Tricuspid Annular Plane Systolic Excursion (TAPSE) (mm)
timeFrame: single time-point at baseline
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: Department of Anesthesiology, University Hospital Basel
Study officials:
affiliation: Department of Anesthesiology, University Hospital Basel
name: Bigna Buddeberg, Dr. med.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01573078: Psychology of Crohn's Disease
Official title: Will The Real Psychology Of Crohn's Disease Please Stand Up?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Crohn's Disease
Keywords: Crohn's disease
IBS
Dissociation
Emotional processing
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2012-04-06
Enrollment: 50
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Crohn's Disease Patients

Brief summary: The purpose of this study is to determine whether emotional processing and somatic dissociation influence IBS-like symptoms in Crohn's Disease patients.


Eligibility criteria: Inclusion Criteria:

* Age of 19 or greater
* Outpatient with diagnosis of Crohn's disease

Primary outcomes:
measure: presence of functional gastrointestinal disorder
timeFrame: within previous 6 months
Secondary outcomes:
measure: difference in ability to process emotions
timeFrame: within previous 6 months
measure: difference in body awareness and degree of bodily-dissociation
timeFrame: within previous 6 months
measure: difference in sensitivity to internal bodily sensations
timeFrame: within previous 6 months
Other outcomes:
Locations:
city: Vancouver
country: Canada
facility: Pacific Gastroenterology Associates
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Robert Enns, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02572778: Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer
Official title: Establishment of Primary Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer for Preclinical Evaluation of Targeted Therapies.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Squamous Cell Carcinoma of the Head and Neck
Lead sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor class: OTHER
First posted: 2015-10-09
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients with a primary advanced or recurrent head and neck tumor.

* Inclusion preoperatively or before biopsy
* Written informed consent prior to surgery or biopsy

Brief summary: The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to:

generate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer

* perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors
* evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options
* evaluate biomarkers of drug sensitivity
* study primary and secondary (acquired) resistance in these models


Eligibility criteria: Inclusion Criteria:

* In the first phase, all patients with primary or recurrent/ metastatic disease of head and neck cancer can be included pre-operatively or before a tumor biopsy after obtaining informed consent
* Data on stage, grade, histology, adjuvant treatment, responses, relapse should be available
* Follow-up data should be available
* Patients with recurrent disease are allowed
* Written informed consent

Primary outcomes:
measure: Identification of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with immunohistochemistry (KI67) on FFPE (fixation followed by paraffin embedding) slides
timeFrame: 10 years
Secondary outcomes:
measure: Characterization of the biomarkers of new cancer therapies for head and neck cancer on the patient-derived xenografts with genetic techniques
timeFrame: 10 years
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Cliniques universitaires Saint-Luc
Study officials:
affiliation: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
name: Jean-Pascal Machiels, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04106778: DMT310-003 Topical in the Treatment of Acne Vulgaris
Official title: A Study of Tolerability, Safety, And Efficacy, Of DMT310 In Patients With Acne Vulgaris
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acne Vulgaris
Lead sponsor: Dermata Therapeutics
Sponsor class: INDUSTRY
First posted: 2019-09-27
Enrollment: 181
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.


Eligibility criteria: Inclusion Criteria:

* Inclusion Criteria:
* Patient is male or non-pregnant female at least 12 years of age.
* Clinical diagnosis of moderate to severe acne vulgaris as determined by:

Investigator's Global Assessment (IGA) at Randomization Patient has at least 20 inflammatory lesions on the face Patient has at least 20 noninflammatory lesions on the face

* Patient is willing to apply the Investigational Product as directed
* Patient is willing and able to comply with the protocol

Exclusion Criteria:

* Patient is pregnant or planning to become pregnant
* Patient is taking a topical therapy on the face which may affect the patient's acne

Primary outcomes:
measure: Efficacy as measured by lesion counts
timeFrame: 12 Weeks
measure: Efficacy as measured by Investigator Global Assessment (IGA)
timeFrame: 12 Weeks
Secondary outcomes:
measure: Incidence of adverse events as a measure of safety and tolerability
timeFrame: 12 Weeks
Other outcomes:
Locations:
city: Austin
country: United States
facility: Dermata Investigational Site
state: Texas
Study officials:
References:
Clinical trial NCT05783778: Evaluation of the Role of Latent Toxoplasmosis in Female Patients With Active Acne Vulgaris
Official title: Evaluation of the Role of Latent Toxoplasmosis in Female Patients With Active Acne Vulgaris
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acne Vulgaris
Toxoplasmosis
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2023-03-24
Enrollment: 200
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Acne vulgaris is one if the most common chronic inflammatory skin disorders.Acne is characterized by forming of inflammatory and non inflammatory lesions mainly on the Face,neck,arms, upper trunk and back

Detailed description: One of the hidden hormonal imbalance is Toxoplasma infection.Toxoplasmosis is a zoonotic infection the definite host is feline whereas human and other warm blooded animals are intermediate host . Endocrine alterations occuring during toxoplasmosis can be a hidden cause of acne vulgaris

Eligibility criteria: Inclusion Criteria:

- Female patients with active acne vulgaris

Exclusion Criteria:

* Patients with history of hormonal treatment Patients received anti toxoplasma therapy Patients with dermatological diseases caused by hormonal disturbances Pregnant and lactating patients

Primary outcomes:
measure: Measuring Toxoplasma igG and free testosterone in acne vulgaris patients and controls
timeFrame: One month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00975078: Test Predicting Adrenal Insufficiency in Volunteers Under Prednisone Treatment
Official title: Dexamethasone-suppression-test Predicts Later Development of Adrenal Insufficiency After a 14 Days' Course of Prednisone in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Adrenal Gland Hypofunction
Keywords: dexamethasone-suppression-test
high dose glucocorticoid treatment
Population at Risk
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2009-09-11
Enrollment: 39
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Suppression of the adrenal function is a common, potentially dangerous and unpredictable consequence of short term high dose glucocorticoid treatment. Identification of patients at risk would be of high clinical importance. The investigators hypothesized that the dexamethasone-suppression-test predicts the subsequent development of corticosteroid induced adrenal insufficiency.

Detailed description: The objective of this study is to evaluate if adrenal axis integrity investigated by the dexamethasone-suppression-test will predict the development of adrenal insufficiency after 14 days treatment with 0.5mg/kg of body weight prednisone in healthy volunteers. The investigators hypothesize that subjects with a more suppressed cortisol level after dexamethasone will be more likely to develop adrenal insufficiency after 14 days intake of prednisone o.5mg/kg/body weight than subjects with less suppression of their cortisol levels after dexamethasone.

Eligibility criteria: Inclusion Criteria:

* Healthy male volunteers over 18 years

Exclusion Criteria:

* No informed consent
* Intake of any kind of medication
* BMI over 30kg/m2
* Acute or chronic illnesses

Primary outcomes:
measure: The primary outcome of this study is the rate of adrenal insufficiency assessed on the 7th day after stopping a 14-days course of corticosteroid therapy with 0.5mg/kg KG prednisone per day.
timeFrame: 7th day after stopping prednisone intake
Secondary outcomes:
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: Division of Endocrinology University Hospital Basel
Study officials:
affiliation: Division of Endocrinology University Hospital Basel
name: Mirjam Christ-Crain, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06748378: Gait Parameters After Using the Tilt-table Exercise and Motor Imagery.
Official title: Analysis of Gait Parameters After Therapy Using the Tilt-table Exercise and Motor Imagery - a Randomized Observational Study on Stroke Patients.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Gait
Visualization
Keywords: Erigo, gait, motor imagery, stroke
Lead sponsor: Military Institute od Medicine National Research Institute
Sponsor class: OTHER
First posted: 2024-12-27
Enrollment: 66
Sex: ALL
Minimum age (years): 30
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Allocation Randomized Interventional Model Parallel Assignment Masking Double (Participant Outcomes Assessor) Primary Purpose Treatment
Primary purpose: TREATMENT

Brief summary: Sixty-six stroke patients were randomly assigned to three groups (conventional, with the addition of the Erigo®Pro table, and enriched with motor imagery). The Trunk Stability Test, walking speed, step symmetry, and lower limb load symmetry on the Riablo device, as well as the superficial tension of the transverse abdominis and multifidus muscles, were assessed before and after completing therapy.

Detailed description: Sixty-six stroke patients were randomly assigned to three groups (conventional, with the addition of the Erigo®Pro table, and enriched with motor imagery). The Trunk Stability Test, walking speed, step symmetry, and lower limb load symmetry on the Riablo device, as well as the superficial tension of the transverse abdominis and multifidus muscles, were assessed before and after completing therapy.

Results: In each of the groups studied, the therapies used significantly improved the functional assessment of trunk stability (Trunk Control Test \<0.001)). Additionally, after the intervention, the Erigo group showed a greater gait speed (p=0.003), while the Visualization group exhibited a higher level of tension in the multifidus (p=0.011) and transverse abdominal muscles (p=0.002).

Eligibility criteria: Inclusion Criteria:

* 1) patients 6-8 weeks post-stroke, 2) aged 38-85 years, mean, 3) males and females, 4) walking with or without assistance (modified Rankin scale = 3), 5) with slight neurological deficits (NIHSS ≤7).

Exclusion Criteria:

* 1) stroke up to six weeks after the episode, 2) epilepsy, 3) no possibility to sit and stand, 4) persistent deficit of speech and cognitive functions, lack of attention, 5) visual disturbances, 6) depression, 7) high or very low blood pressure, dizziness, malaise.

Primary outcomes:
measure: Trunk Control Test
timeFrame: two weeks
Secondary outcomes:
measure: RiabloTM device
timeFrame: two weeks
measure: Luna EMG
timeFrame: two weeks
Other outcomes:
Locations:
city: Warsaw
country: Poland
facility: Military Institute of Medicine National Research Institute
state: Masovian District
Study officials:
References:
Clinical trial NCT03877978: Acute Kidney Attack in Severe Traumatized Patients
Official title: Evaluation of the Incidence of Acute Kidney Attack by Dosing Nephrocheck® in Severe Traumatized Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Kidney Injury
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2019-03-18
Enrollment: 196
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Severe traumatized patients with an ISS ≥ 15 admitted to the trauma center of Edouard Herriot Hospital

Brief summary: Acute Kidney Injury (AKI) is a common complication of severe traumatized patients. The diagnosis is often delayed. The Nephrocheck® test allows an earlier assessment of renal stress. The objective of our study is to determine the incidence of risk of AKI in severe traumatized patients within the first 24 hours after their admission to our trauma center. The risk of AKI is defined by a NephroCheck® test \>0.3


Eligibility criteria: Inclusion Criteria:

* age \>18 years
* trauma patients with ISS ≥15
* patient admitted to the resuscitation bay of Edouard Herriot Hospital

Exclusion Criteria:

* anuric patient
* opposition of the patient (or a trusted person) to participate
* pregnant or lactating woman
* age \<18 years

Primary outcomes:
measure: Incidence of patients with Nephrocheck score > 0,3
timeFrame: Up to 24 hours after trauma
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hôpital Edouard Herriot
Study officials:
affiliation: Intensive Care Unit, Pavillon H - Réanimation chirurgicale. Edouard Herriot hospital 5 place d'Arsonval - 69003 Lyon FRANCE
name: Violette Zorio
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04352478: Incidental Cancer in Gallbladder Surgical Specimens Focus on Elderly Patients
Official title: Incidental Cancer in Gallbladder Surgical Specimens Focus on Elderly Patients, Retrospective Analysis of 2389 Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pathology
Keywords: cholecystectomy
cholecystitis
cholelithiasis
gallbladder neoplasms
histopathology
surgical procedures
Lead sponsor: Dr. Ersin Arslan Education and Training Hospital
Sponsor class: OTHER_GOV
First posted: 2020-04-20
Enrollment: 2389
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who underwent cholecystectomy between January 2016 and February 2020 at our hospital

Brief summary: Causes such as long-term stones and polyp are thought to play a role in the etiology of gallbladder cancer. The routine histopathological examination provides the detection of incidental gallbladder cancers. It should be remembered that acute or chronic cholecystitis accompanied by the thicked wall and a prolonged history of gallstones may be the cause of malignancy, especially in elderly patients.

Detailed description: The investigators aimed to incidental gallbladder cancer and compare other pathology results with elderly patients.

Eligibility criteria: Inclusion Criteria:

* acute cholecystectomy
* elective cholecystectomy

Exclusion Criteria:

* lack of data
* incidental cholecystectomy,
* cholecystectomy secondary to trauma
* cholecystectomy secondary to malignancy

Primary outcomes:
measure: Rate of Incidental Cancer
timeFrame: 2 or 3 week
Secondary outcomes:
Other outcomes:
Locations:
city: Gaziantep
country: Turkey
facility: Dr. Ersin Arslan Training and Resource Hospital
Study officials:
affiliation: Dr. Ersin Arslan Training and Resource Hospital
name: Ufuk Uylas
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00808678: Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Adverse Events
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-12-16
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.


Eligibility criteria: Inclusion Criteria:

1. A condition of general good health
2. BMI 19 to 29

Exclusion Criteria:

1. Currently enrolled in another clinical study
2. Females who are pregnant or breast-feeding

Primary outcomes:
measure: To determine the safety and tolerability of ABT-143 vs (ABT-335 + rosuvastatin) in healthy adults
timeFrame: 7 days
measure: To determine the pharmacokinetic profile(s) for ABt-143 vs. (ABT-335 + rosuvastatin) in healthy adults
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Orlando
country: United States
facility: Site Reference ID/Investigator# 14762
state: Florida
Study officials:
affiliation: AstraZeneca
name: Torbjörn Lundström, MD
role: STUDY_DIRECTOR
References: